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Dear Dr. Danielle Loughlin, 
 
Ms number: TCB-D-17-00020 
 
Please find enclosed our revised manuscript with new title, Spatial and Temporal 
Control of Senescence. 
 
Thank you again for your guiding us to revise the manuscript. It has been very 
helpful. We have incorporate most of your suggestions. Together with our response to 
reviewers’ questions, some point needed further consideration. Particularly we have 
kept some flow within the text and some sub-titles (in Introduction), which may help 
readers to follow the now longer introduction. Also we have tried to broaden the 
content, but the manuscript is still focused on Notch, which was our initial agreement.  
 
We also thank all the reviewers for their careful reading and constructive comments. 
We have modified the manuscript accordingly. We believe the modifications have 
substantially improved our manuscript. 
 
Thank you again for your help. 
 
Sincerely, 
 
Masashi 
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Ms number: TCB-D-17-00020 
 
 
We thank the reviewers for their careful reading and thoughtful comments, and the 
editor for her helpful guidance.  
 
The major changes made in this revision are: 
 
x The structure of the main text has been changed as comments/suggestions 
from the reviewers and the editor. 
 
x The order of  (original) Figure 2 and 3 has been changed as the editor’s 
suggestion. Now Figure 2 introduces NOTCH signaling and Figure 3 shows 
the model of RIS- and RAS-type senescence. 
 
x The changes other than above can be found in ‘Point-by-point response’. 
 
 
 
Point-by-point response: 
 
Reviewer #1 
In this review Ito et al. summarize the state-of-affairs of the senescence-associated 
phenotype in health and disease. The authors succinctly describe historical and 
recent developments and interlace them with their own, recently published findings. 
Overall the review is quite-well balanced but not very accessible to non-specialists. 
In addition, their own contribution should be toned down. 
We agree this is a valid point, which was also raised by the editor. Although, the 
main focus of the review article is still NOTCH, we have broadened the scope and 
avoided any overstatements.  
 
1. Globally speaking the phrasing and wording are at times too convoluted and the 
sense of some sentences is hard to decipher. The abstract as is not very enticing 
and too narrowly phrased for a wider audience. 
 We have rephrased the abstract for a wider audience.  
 
1-1 I would not go so far to say that NOTCH is a master regulator. How important it 
really is needs to be seen. Tone down. 
We agree. We have removed the word “master”. 
 
1-2 page 1 in abstract: ...leading to a stable cc arrest.... 
Corrected. 
 
1-3 in abstract: ...leading to complex non-autonomous functionality through the 
SASP: what is meant to be said here? 
This has been rephrased as follows (now page 1, line 17): 
 
“Senescent cells are highly secretory driving a range of different functions through 
the senescence-associated secretory phenotype (SASP).” 
Response to Reviewers
 
1-4 in Figure 1: telomere (not telomer) dysfunction and developmental cues are 
missing. Moreover, I think premature senescence is a misnomer because this is only 
relative to replicative senescence. Physiologically speaking it is not premature but 
right in time. So, I would replace here with cellular senescence. The distinction is not 
necessary. 
We thank the reviewer for pointing this. We have corrected the typo and added: 
“developmental cues” as triggers of senescence in fig. 1. We have also used 
“Cellular senescence” to represent the phenotype in fig. 1 as suggested. 
 
1-5 page 2 line 11 cell autonomous; ...damage from theses stressors...: from which 
ones; I presume the ones that are mentioned two sentences before. 
Yes. This sentence has been moved later in the manuscript and rephrased as 
follows (now page 2, line 21): 
 
“senescence is an essential autonomous tumor suppressor mechanism preventing 
accumulation of damaged cells and malignant transformation.” 
 
1-6 yes, the commonality is that the mentioned stressors are all potentially 
oncogenic but not all senescence inducers are. I think the distinction between 
physiological and patho-physiological senescence should be highlighted better in this 
paragraph up front. 
We have clarified that senescence is involved in both pathological and physiological 
processes, citing figure 1, and also in the following ‘SASP section’.   
 
1-7 cytotoxic drugs also induce senescence (TIS) and it is mostly independent of p53 
and Rb status, so here the senescence response is dormant. This should be 
mentioned and weaved into the text. The importance of the SASP in such a context 
could be discussed. 
We have added the description that TIS can be independent of p53/Rb, which are 
often defective in cancer. Also, a potential tumorigenic effect of the SASP in this 
context has been mentioned (now page 3, line 8).  
 
1-8 line 25: Indeed, senescence confers diverse impacts....should read senescence 
impacts.... 
This sentence has been moved to the ‘SASP section’ and rephrased.  
 
1-9 page 3 line 3: ...developing placenta, embryo and.... 
1-10 line 4 sense: In both situations...but there are more than two here. 
We have rephrased to make the statement more accurate and up-to-date as follows 
(now page 3, line 22): 
 
“Many recent works have clarified the importance of senescence not only as an 
intrinsic tumor suppressor, but as a highly conserved mechanism underpinning 
development and homeostasis; physiological senescence has been reported in the 
developing placenta [18], embryo [19,20] and during wound healing [21,22], driving 
the appropriate development or restoration of tissue architecture, often through 
immune surveillance. Moreover, the SASP, and IL6 in particular, has been 
demonstrated to promote cellular reprogramming [23-26].” 
 
1-11 line 9: How important the SASP is for development is currently only speculative. 
Thus, I would avoid "critical" here as a judgment or ref the proof. 
We agree and have deleted “critical”. 
 
1-12 line 3: cite primary publications here rather than own reviews (Gil and Peeper 
and Campisi). 
These primary papers have been cited as suggested.  
 
1-13 line 16: The SASP includes many pleiotropic factors, driving different, 
potentially contrasting, impacts on different target cells. Rephrase sentence to read 
easier. I now what wants to be said here but the construction is too heavy. 
This has been rephrased as follows (now page 3, line 6): 
 
“The SASP has been linked to highly context-dependent and sometimes contrasting 
downstream functional outcomes.” 
 
1-14 page 4 line 6: The transition sentence is odd and should be rephrased. 
 This has been rephrased (now page 4, line 15). 
 
1-15 line 19: What is meant here? What interaction are we talking about? Functional 
or direct prot-prot; gene network...Please, clarify. 
page 5 line 8: "are" instead of "were also unclear". 
We have rephrased this sentence as follows (now page 5, line 13): 
 
“How BRD4 activity integrates with NF-κB and C/EBPβ activity to influence SASP 
gene expression remains unknown.” 
 
1-16 lines 10-13: This paragraph should be deleted. I think their own contribution 
should be humbled in a review. Any we etc should be avoided whenever possible. 
- Put a transition sentence here. 
‘We’ etc have been deleted but we have kept the paragraph to clarify that this review 
is focused on ‘NOTCH-mediated senescence control’ (this was the initial agreement 
with the editor). 
 
1-17 page 10 line 16: It should be discussed why dynamic NOTCH activity could be 
important for OIS. 
This is an important and interesting point. In the original version, we extensively 
discussed the potential significance of dynamic NOTCH regulation in tissue 
remodeling. However, it is unclear how it is also important for OIS. We speculate that 
at an early stage of OIS, NOTCH signaling might serve as amplification machinery 
for pro-senescence TGFb signaling to ensure senescence establishment. And then 
timely switch to inflammatory SASP would facilitate senescence surveillance. This is 
highly speculative, thus discussed in the section ‘conclusion remarks’.  
 
1-18 page 24 line 11: This conditioned media..should read These...or 
This...medium... 
As the editor’s suggestion, we have deleted all the glossary terms. 
 
1-19 Trends box: cell-cell contact rather than cell-contact 
Corrected. 
 
2. Given the latest findings by Keyes et al in Genes/Dev and Serrano et al in Science 
this information should be included because it supports the argument of a dynamic 
SASP function. 
This is a good point. We have added the information about the SASP-cell plasticity 
on page 4, line 2. 
 
We also include a speculative view regarding the Notch-cell plasticity connection at 
the conclusion section.  
 
3. The conclusion again is quite narrow and should express research opportunities 
and future directions more vividly. 
We have removed notch-specific discussions and, instead, have added some 
particularly speculative views. At the same time, we have modified  ‘outstanding 
questions’ to make less Notch-centric.  
 
 
 
Reviewer #2  
This manuscript is a review about the Notch signalling pathway in the context of 
senescence. Following their publication on 2016, where they described NOTCH1 as 
the master controller of the switch between two different secretomes, they here offer 
an extended discussion of the role NOTCH plays regarding SASP control and the 
non-cell autonomous spatial propagation of senescence phenotype. Overall, this is a 
well-written discussion about the novel role of NOTCH1 in senescence (recently 
described by Narita´s laboratory).  
 
1. Although this review is focused on NOTCH1, as it´s the protein of interest of their 
recent publication, I would suggest adding more background and discussion about 
the other three NOTCH receptors and their role in senescence. 
Other Notch receptors have also been linked with senescence. Although these 
studies were cited in the original version, we failed to describe the finer details. We 
have now extended the background of individual Notch receptors, particularly in the 
senescence context as follows (now page 7, line 19): 
 
“NOTCH can also drive senescence independently of other stressors as ectopic 
expression of the ICDs of all of the NOTCH receptors induces senescence [52-54]. 
Upregulation of some cyclin-dependent kinase (CDK) inhibitors has been 
demonstrated as the molecular mechanism for NIS. Ectopic NOTCH3 in HMECs 
leads to upregulation of p21 through direct binding to its promoter [54]. Ectopic 
N1ICD leads to NIS through transcriptionally upregulating p16, and subsequent 
activation of Rb [53].” 
 
2. In their current proposed model, an initial wave of NOTCH-TGFB signaling 
associated to an specific secretome preceded a second NFKB-CEBPB specific 
"canonical SASP" phase where TGFB signaling is switched off. However, others 
have shown that some factors of the TGFB family such as INHBA sustained TGB 
signaling during the late "canonical SASP" phase and are important for some 
senescence non autonomous effects such as paracrine senescence. authors should 
discuss how these other TGFB-family factors such as INHBA or BMPs fit into the 
proposed model. 
The following discussion has been added (now page 12, line 1): 
 
“A recent study of OIS has reported persistent upregulation of other TGF-β family 
ligands, such as the activin/inhibin subunit, inhibin beta A (INHBA) [13]. Although 
INHBA is upregulated to similar levels in both RIS and NIS, endogenous activin 
antagonists follistatin-like 3 and BAMBI are both downregulated in RIS and 
upregulated in NIS (unpublished data), suggesting further potential post-translational 
switching in TGF-β signaling by NOTCH and RAS. “ 
 
3. The bibliography is well chosen and up to date with some exceptions that have 
been stated in the comments. 
In general and after some additions this would be a good review and I recommend 
its published in your journal. 
We have added new references as suggested.  
 
Reviewer #3 
Comments on "Notching up and down: temporospatial control of senescence" by Ito 
et al 
 
Overall, this is a very well written article, very nicely summarizing the recent finding 
by the group on the role of a Notch-mediated switch in the senescence-associated 
secretory phenotype, and the novel implications for senescence in general. The 
introduction and context of senescence and the SASP is well written for non-experts 
in the field to understand the context and significance. The details of their discovery 
and the mechanisms are well explained and discussed. In general, this reviewer only 
has some very minor comments on spelling and typing mistakes, and congratulate 
the authors on a very nice piece. 
 
Minor comments 
 
1. In the first paragraph on page 8, the sub-heading is "Two types of SASP", 
whereas in the text, they more so describe different stages in the temporal evolution 
of the senescence program. This is a little confusing suggesting two separate 
processes, rather than two stages of the same process. Perhaps the subheading 
could read "Two stages of the SASP" or something similar. 
We thank the reviewer for pointing this out. We have replaced the sub heading with  
‘NOTCH-mediated secretome switch’. 
 
2. Telomere misspelled in fig 1 
Corrected. 
 
3. p3, Line 4: should not use "both" situations: 
This has been clarified. Please see our response to reviewer #1-1-10 
 
4. p5, Line 15: evolutionarily misspelled 
Corrected. 
 
5. p7, line 4: avoid repeated use of "more" 
Corrected.  
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Abstract  15 
Cellular senescence is an autonomous tumor suppressor mechanism leading to a 
stable cell cycle arrest. Senescent cells are highly secretory driving a range of 
different functions through the senescence-associated secretory phenotype (SASP). 
Recent findings have suggested that the composition of the SASP is dynamically 
and spatially regulated and that the changing composition of the SASP can 20 
determine the beneficial and detrimental aspects of the senescence program, tipping 
the balance to either an immunosuppressive/pro-fibrotic environment or pro-
inflammatory/fibrolytic state. Here we discuss the current understanding of the 
temporal and spatial regulation of the SASP and the novel finding of NOTCH 
signaling as a regulator of SASP composition.  25 
  
Manuscript Click here to download Manuscript Main
Text_resubmission_YI.docx
 2 
Cellular senescence and its secretory phenotype 
Cellular senescence was originally identified as a loss of proliferative capacity after 
prolonged culture of human diploid fibroblasts (HDFs) [1,2]. This form of 
senescence, induced by ‘replicative exhaustion’ and thus called replicative 
senescence, was later shown to be due to telomere attrition. Although replicative 5 
senescence was the prototypic form of senescence, similar phenotypes can be 
induced by a wide-range of stresses, including oxidative and genotoxic stress, 
cytokines, chromatin perturbation and unrestricted activation of oncogenes or 
mitogens [3,4]. Thus, senescence is a collective phenotype found in a range of cell 
and tissue types with diverse triggers, both pathological and physiological (Figure 1). 10 
An essential feature of senescence is persistent cell cycle arrest, which is 
unresponsive to extrinsic growth factor signals [1]. This arrest is most obviously 
demonstrated in oncogene-induced senescence (OIS), where cells stop proliferating 
even in the presence of continuous activation of the RAS/MAPK pathway, 
underscoring the tumor suppressive role of senescence. Critical to the senescent 15 
phenotype is activation of the p53-p21 and p16-retinoblastoma protein (Rb) 
pathways; loss of these pathways, as occurs in many human cancers, permits 
senescence-bypass and tumorigenesis. Importantly this phenotype can be vital in 
the response to some anti-cancer treatments, termed therapy induced senescence 
(TIS) [5,6]. Appropriate development of tumoral senescence after chemotherapy 20 
underpins tumor regression and improved prognosis [7]. Thus, senescence is an 
essential autonomous tumor suppressor mechanism preventing accumulation of 
damaged cells and malignant transformation.  
 
 3 
Senescent cells also have significant non-cell-autonomous activities, which are 
crucial for many facets of senescence in vivo, including tumorigenesis, tissue repair, 
and embryological development. Soluble proteins secreted by senescent cells 
include inflammatory cytokines, chemokines, growth factors, and matrix-modifying 
enzymes, contributing to the senescence-associated secretory phenotype (SASP) 5 
[8-10]. The SASP has been linked to highly context-dependent and sometimes 
contrasting downstream functional outcomes. The SASP can be tumorigenic and 
promote the growth of neighboring transformed cells [10-12]. This is particularly 
significant in the in vivo TIS context, where the SASP (either from TIS or stromal 
senescent cells) could facilitate tumor recurrence from residual non-TIS or 10 
‘incomplete’ TIS cancer cells, which are often p53/Rb defective [5,6].  However, in 
other contexts the SASP can be tumor suppressive, with induction (e.g. TGF-β 
[13,14]) or reinforcement (e.g. IL6, IL8 [8-10]) of a senescent phenotype in 
neighboring ‘normal’ cells (Figure 1). In addition, secretion of inflammatory cytokines 
by senescent cells has profound effects upon the immune system. The SASP can 15 
drive recruitment and activation of immune cells with subsequent removal of the 
senescent cell, termed senescence surveillance [15-17]. This senescence 
surveillance is important for the tumor suppressive role of senescence as inhibition 
or loss of immune mediators allows chronic persistence of senescent cells and 
subsequent tumorigenesis [17].  20 
 
Many recent works have clarified the importance of senescence not only as an 
intrinsic tumor suppressor, but as a highly conserved mechanism underpinning 
development and homeostasis; physiological senescence has been reported in the 
developing placenta [18], embryo [19,20] and during wound healing [21,22], driving 25 
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the appropriate development or restoration of tissue architecture, often through 
immune surveillance. Moreover, the SASP, and IL6 in particular, has been 
demonstrated to promote cellular reprogramming [23-26].  
 
Senescence is a fundamental intrinsic pathway arising in a variety of situations, 5 
whose appropriate function depends on its secretome. The SASP drives a wide 
range of potentially contrasting outcomes, requiring complex regulatory mechanisms. 
Understanding these mechanisms could permit therapeutic targeting of the SASP to 
promote an anti-tumorigenic response [27]. This review will focus on the temporal 
and spatial regulation of SASP composition and function, as well as novel contact-10 
dependent cell signaling pathways in senescence, including NOTCH signaling 
(Figure 2).   
 
SASP regulation 
The realization that the SASP can have contrasting physiological functions has 15 
sparked interest in understanding its regulation. However, how the net functional 
output of such a complex entity is regulated has been unclear. Regulation of the 
SASP has been linked to signaling pathways, such as the DNA damage response 
(DDR) [28], p38MAPK [29,30], JAK/STAT [27], the inflammasome [13] and 
autophagy/mTOR [31-35]. Although some SASP effectors seem to act post-20 
transcriptionally [31-33], most SASP regulators converge on two transcription 
factors, NF-κB and C/EBPβ, which co-operatively regulate many SASP components 
and inflammatory cytokines [8,9,34,36,37]. Originally, IL6 was proposed to be a 
central regulator of the inflammatory SASP; depletion of IL6 in the context of OIS 
results in collapse of the network, where a positive feedback loop between IL6 and 25 
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the transcription factors, C/EBPβ and NF-κB is engaged [9]. Later it was shown that 
IL1α, which can activate C/EBPβ and NF-κB, is upstream of IL6 in SASP control 
[38]. Indeed, ectopic expression of IL1α is able to phenocopy many aspects of RAS-
induced senescence (RIS), including expression of IL6, IL8 and CCL2 [13]. Thus, 
proximal cytokines and inflammatory transcription factors act in a positive feedback 5 
loop to amplify the signaling of the SASP (Figure 3A).  
 
More recent work has expanded our understanding of this signaling network: GATA4 
has been recognized as an upstream regulator of NF-κB signaling in senescence. 
Activation of the DDR leads to GATA4-dependent activation of NF-κB and hence 10 
SASP expression [34]. The chromatin reader protein BRD4 is another newly 
identified regulator that dynamically binds to super-enhancer elements adjacent to 
inflammatory SASP genes [39]. How BRD4 activity integrates with NF-κB and 
C/EBPβ activity to influence SASP gene expression remains unknown.  
 15 
Therefore, whilst our understanding of the regulation of the inflammatory SASP has 
improved, understanding of other SASP modules and whether they are regulated 
through other pathways is less explored. However, it has become clear that the 
composition of the SASP can be modulated to achieve anti-tumorigenic effects [27]. 
 20 
Senescence is a progressive phenotype and there is some evidence that global 
SASP functionality is also temporally regulated. Senescent cells accumulate in skin 
wounds where they act to promote wound healing. Senescent cell secretion of 
PDGF-AA promotes wound closure and deletion of these senescent cells delays 
wound healing. However, senescent cells also subsequently drive their own immune-25 
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mediated clearance, suggesting a temporal switch from orchestration of wound 
repair to inflammatory recruitment of immune cells [22]. Consistently, a recent study 
has begun to unpick the mechanistic underpinnings of the temporal regulation of the 
SASP, suggesting that there are at least two distinct types of SASP: a ‘NOTCH-
induced senescence (NIS) type’ (or ‘TGF-β type’); and a ‘RAS-induced senescence 5 
(RIS) type’ (or ‘inflammatory type’) [40] (Figure 3A).   
 
NOTCH in senescence 
NOTCH is an evolutionarily conserved family of four cell surface receptors that play 
an essential role in embryonic development controlling cell fate determination and 10 
tissue homeostasis in many adult tissues [41,42]. The functions of NOTCH signaling 
are highly tissue-type specific, either promoting or inhibiting cell proliferation, viability 
and differentiation. In addition, since NOTCH ligands, such as the DLL and JAG 
family of proteins, are also plasma membrane proteins, NOTCH signaling is 
mediated through cell-cell contact, contributing to complex bio-patterning that is 15 
dependent on ‘specification’ of both signal-sending (ligand expressing) and signal-
receiving (receptor expressing) cells [43] (Figure 2, Box 1).  
 
Upon ligand-receptor interaction, NOTCH receptors undergo a series of proteolytic 
cleavages liberating the active NOTCH intracellular domain (NICD). NICD 20 
translocates to the nucleus, where it forms a complex with the DNA-binding 
transcription factor RBP-J and the co-activator Mastermind-like 1 (MAML1) proteins. 
RBP-J is a transcriptional repressor, which is converted to a transcriptional activator 
when bound to the NICD driving expression of NOTCH-target genes such as the 
HES and HEY family of transcription factors [41,43] (Figure 2).  25 
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NOTCH can be oncogenic or tumor suppressive in different cancer types. Indeed, 
constitutively active NOTCH is oncogenic in T-cell acute lymphoblastic leukaemia (T-
ALL) [44,45], while NOTCH can be tumor suppressive in both bladder and head and 
neck squamous cell cancer [46,47]. The basis for this context-dependent duality is 5 
unclear, but one hypothesis is the complex interaction between cancer and tumor 
stroma as NOTCH signaling in stromal cells has been shown to modulate the tumor 
microenvironment [48].  
 
Hyperactive Notch1 signaling can induce cell cycle arrest and apoptosis in early 10 
neural progenitor cells [49] and mouse embryonic fibroblasts  [50], but its role in 
senescence was unclear until recently. Several NOTCH receptors or components of 
NOTCH signaling are upregulated during different forms of stress-induced 
senescence in various cell types, including human and mouse fibroblasts, human 
endothelial cells, human umbilical vein endothelial cells (HUVEC), human 15 
esophageal keratinocytes, human mammary epithelial cell (HMEC), and mouse 
primary renal tubular epithelial cells (PTEC) [51-55]. Inhibition of Notch, usually 
through γ-secretase inhibition (Figure 2), prevents or delays senescence in most 
models. NOTCH can also drive senescence independently of other stressors as 
ectopic expression of the ICDs of all of the NOTCH receptors induces senescence 20 
[52-54]. Upregulation of some cyclin-dependent kinase (CDK) inhibitors has been 
demonstrated as the molecular mechanism for NIS. Ectopic NOTCH3 in HMECs 
leads to upregulation of p21 through direct binding to its promoter [54]. Ectopic 
N1ICD leads to NIS through transcriptionally upregulating p16, and subsequent 
activation of Rb [53]. Whilst different Notch receptors are upregulated or activated in 25 
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various senescence models, the basis of determination between NOTCH-mediated 
apoptosis and senescence is unclear. In addition, the functional relevance of 
NOTCH signaling in the downstream functions of senescence has been largely 
unexplored. 
 5 
NOTCH-mediated secretome switch 
NOTCH1 was found to be significantly upregulated in RIS through plasma 
membrane proteomics [40]. Whilst NOTCH1 receptor expression is continuously 
upregulated during RIS, downstream signaling from NOTCH1 occurs transiently at 
the early phase of RIS or DNA damage-induced senescence (DDIS) (Figure 3A). 10 
NOTCH1 activity closely correlates with the expression of both TGF-β1 and TGF-β3 
and inversely correlates with typical inflammatory cytokines, such as IL1α, IL6 and 
IL8. Indeed, NOTCH1 signaling is necessary and sufficient for TGF-β1 upregulation 
in RIS cells, whereas it negatively regulates expression of inflammatory cytokines. 
This suggested that there might be at least two distinct phases of SASP during 15 
senescence. Transcriptional profiling found that this regulation was not restricted to a 
few canonical SASP cytokines, but a generalized NOTCH-mediated reprogramming 
of the secretory output of the senescent cell. While the RIS-type SASP included 
many well-known inflammatory factors, shown by other groups [10,56,57], NIS was 
accompanied by expression of a distinct set of secreted factors. These two distinct 20 
secretomes exhibit a strikingly reciprocal pattern: RIS factors are mostly 
downregulated in NIS cells whereas NIS factors tend to be downregulated in RIS 
cells [40]. Furthermore, sustained activation of NOTCH1 in late RIS cells results in a 
SASP more similar to the NIS-type SASP, indicating a dominant role for NOTCH in 
determining SASP composition: the higher the NOTCH activity, the stronger the 25 
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TGF-β type components. This model suggests that the dynamic nature of NOTCH1 
activity contributes to a switch between these two SASPs during senescence.  
 
One of the key unanswered questions is how the level of NOTCH signaling is 
regulated during senescence. There are a number of potential candidates, including 5 
activity of the gamma-secretase complex and endogenous NOTCH inhibitors such 
as NUMB, IKAROS, ITCH and FBXW7 [58-60].  However, further investigations will 
be required to understand this mechanism and whether it could be targeted. 
 
Modulation of senescence surveillance by NOTCH 10 
The inflammatory SASP is critical for senescence surveillance where immune cells 
are recruited to eliminate senescent cells, thereby preventing tumorigenesis 
[17,27,61,62]. Therapeutics can reprogram the SASP to promote senescence 
surveillance [27]; therefore, de-repression of the inflammatory SASP through 
NOTCH-inhibition could promote this process. Utilizing a NRASG12V-driven murine 15 
hepatocyte senescence model, where RIS hepatocytes are progressively cleared by 
a CD4+ T-cell-dependent immune reaction [17], autonomous inhibition of Notch 
activity accelerates clearance of senescent cells, with increased T-cell recruitment 
[40]. NOTCH modulation has been considered in cancer therapy [63,64], and this 
study implies that NOTCH could be considered a target for preneoplastic lesions in 20 
early therapy for the prevention of malignancy, at least in some tissue types. 
 
NOTCH negatively regulates C/EBPβ 
Whilst NOTCH activity tunes the SASP composition during senescence, this does 
not exclude the hierarchical model of inflammatory-type SASP regulation, which 25 
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involves proximal cytokines (IL1α in particular) and the transcription factors, NF-κB 
and C/EBPβ. NOTCH1 negatively regulates C/EBPβ in RIS (Figure 3A), while NF-κB 
activity is largely unaffected [40], despite previous studies suggesting significant 
crosstalk between these two pathways [65]. 
 5 
Notably, although IL1B/6/8 are well known targets of C/EBPβ, how IL1A is regulated 
is unclear. Similarly to IL1β/6/8, IL1α activates C/EBPβ (and NF-κB) [38], and 
C/EBPβ directly induces IL1A, which can be disrupted by NOTCH through depletion 
of C/EBPβ from an IL1A enhancer. Indeed, chromatin-binding profiles demonstrate 
that C/EBPβ binds to prominent upstream enhancer regions of IL1A although it also 10 
seems to bind the core promoter more weakly. The latter might be a reason for the 
apparent lack of evidence for the direct regulation of IL1A by C/EBPβ. These 
upstream enhancers directly associate with the IL1A promoter as shown by high-
throughput 3D chromatin interactome mapping in HDFs, suggesting that they are 
IL1A enhancers [66]. Similarly C/EBPβ was found to predominantly bind one of the 15 
enhancer regions rather than the core promoter of IL1A during RIS, and this 
interaction was reduced by ectopic N1ICD expression [40] (Figure 3B).  
 
Considering the central role for IL1α in the induction and subsequent amplification of 
the inflammatory SASP [13,38], NOTCH could provide a highly sensitive and robust 20 
mechanism of global SASP regulation. This view is corroborated with the near 
mutually exclusive NIS- and RIS-type secretome profiles (Figure 3A). Moreover, the 
pleiotropic activities of both factors suggest that such a regulatory relationship 
between C/EBPβ and NOTCH may have wider implications in development, 
differentiation, and cancer biology. 25 
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NOTCH and TGF-β 
TGF-β is an important SASP factor that has major roles in several contexts. Firstly, it 
underpins paracrine senescence through p21-mediated cell cycle arrest. Co-culture 
of normal target cells with cells undergoing various types of senescence, or culture 5 
of normal cells in conditioned medium leads to target cell senescence, which is 
dependent on TGF-β and IL1β. [13,14]. Secondly, TGF-β seems to be crucial for the 
downstream functionality of the recently described developmental senescence [19].  
 
Whilst often cytostatic, the effect of TGF-β on cell proliferation is cell-type dependent 10 
[67]. TGF-β alone fails to induce senescence in HDFs, but NIS is, in part, dependent 
on TGF-β [40]. Thus, TGF-β must cooperatively activate the NIS phenotype with 
other factors. How NOTCH activates TGF-β during senescence is still unclear. The 
relationship between NOTCH and TGF-β is complex and they crosstalk at various 
levels. Functionally, they often cooperate to induce target genes of either or both 15 
signaling pathways [68-70] although they can be mutually antagonistic in some 
contexts, such as muscle aging [71]. For their regulatory relationship, most studies 
have focused on TGF-β-driven induction of the NOTCH ligand JAG1 [69,72,73]. A 
positive feedback between these signals could be observed in renal podocytes and 
prostate epithelial cells [74,75]. Indeed, TGF-β-induced senescence in human 20 
esophageal keratinocytes is mediated through JAG1/NOTCH1 activation [53]. In 
contrast, another study found that JAG1 induction is TGF-β-independent, despite 
NOTCH-dependent upregulation of both factors. Therefore, NOTCH1 activation can 
be an upstream event of TGF-β activation during senescence, reinforcing the idea 
that NOTCH1 is a master modulator of SASP composition [40]. 25 
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A recent study of OIS has reported persistent upregulation of other TGF-β family 
ligands, such as the activin/inhibin subunit, inhibin beta A (INHBA) [13]. Although 
INHBA is upregulated to similar levels in both RIS and NIS, endogenous activin 
antagonists follistatin-like 3 and BAMBI are both downregulated in RIS and 5 
upregulated in NIS (unpublished data), suggesting further potential post-translational 
switching in TGF-β signaling by NOTCH and RAS.  
 
Spatial regulation of senescence 
Previous studies have demonstrated that non-cell-autonomous signaling from 10 
senescent cells is spatially restricted. RIS HDFs co-cultured with normal HDFs are 
able to non-cell-autonomously transmit a senescent phenotype to adjacent normal 
cells, but the effect wanes with distance from the RIS cells [13]. Similarly, this 
‘paracrine’ senescence is incomplete as onward transmission declines with distance 
from the primary senescent cells. This could prevent runaway senescence and 15 
inflammation taking hold throughout a tissue, but its underlying mechanisms are ill-
understood. One plausible mechanism is a cell-cell contact-dependent form of 
signaling rather than solely through the SASP; the non-cell-autonomous function of 
senescent cells was thought to lie predominantly in their secretome and cell-cell 
contact-dependent mechanisms have not previously been described in senescence. 20 
NOTCH is known to drive signaling through cell-cell contact-dependent feedback 
loops that involve the induction or repression of NOTCH ligands on adjacent cells. 
During lateral induction NOTCH-mediated upregulation of NOTCH ligands leads to 
the transmission of NOTCH signals to neighboring cells; this mode of signaling is 
responsible for coordinated cell behavior across a tissue [76,77] (Box 1). An 25 
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analogous process has been shown to occur during senescence: the NOTCH ligand 
JAG1 is selectively upregulated by N1ICD, as well as during the early phase of RIS. 
Co-culture experiments show that the NIS phenotype is transmitted to neighboring 
‘normal’ cells, where JAG1-high NIS cells induce NOTCH signaling in the 
neighboring cells. This positive feedback loop leads to spatial relay of NIS. 5 
Therefore, senescence-associated NOTCH-dependent upregulation of JAG1 is 
linked to a spatial expansion of the NOTCH-driven phenotype of senescence and 
secretome control. This lateral induction of NOTCH signaling can be observed in 
vivo during RIS in hepatocytes [40]. 
 10 
A recent study has also highlighted other cell-cell contact-dependent signaling in 
senescence. Senescent cells, both in vitro and in vivo, are able to transfer proteins to 
neighboring cells through cytoplasmic bridges; in this model juxtacrine protein 
transfer from senescent cells to immunocytes was able to facilitate immune-
mediated surveillance of senescent cells and could be demonstrated in vivo from 15 
KrasG12D-expressing pancreatic cells to immunocytes [78]. Therefore, more than 
simply reliant on the SASP, senescent cells are able to demonstrate complex cell-
cell contact-dependent signaling patterns that necessarily result in spatially-restricted 
patterns of behavior preventing widespread changes throughout tissues. It will be 
fascinating to see the physiological and pathophysiological relevance of this in the 20 
future. 
 
Senescence and tissue homeostasis 
The NOTCH-mediated temporal regulation of the SASP is probably not limited to 
RIS, given the similarity between the dynamic pattern of NOTCH1 activity and TGF-β 25 
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expression in RIS and DDIS [40]. The two secretomes also appear to represent 
distinct functionalities. TGF-β signaling is immunosuppressive [79], and also plays a 
key role in fibrosis upon tissue damage; type 3, 4 collagens and Fibronectin1 (FN1), 
constituents of fibrotic tissues, are also upregulated in NIS cells. In addition to pro-
inflammatory cytokines, the RIS-type SASP components include extracellular matrix-5 
degrading metalloproteases, such as MMP1/3/10 [16,40]. Therefore, the 
NOTCH/TGF-β-high and the NOTCH/TGF-β-low phases of senescence might 
modulate the extracellular matrix through pro-fibrotic and fibrolytic functions, 
respectively.  
 10 
This is highly reminiscent of the dynamic alteration of the secretome of hepatic 
stellate cells (HSCs). This liver-resident cell responds to organ damage through 
activation and secretion of a pro-fibrotic secretome leading to hepatic fibrosis, 
potentially underpinned by NOTCH [80]. Post-activation, HSCs undergo senescence 
with a pro-inflammatory, fibrolytic SASP, thereby both contributing to the resolution 15 
of fibrosis and their own immune-mediated clearance [16]. Similar to RIS HDFs [40], 
matrix components such as type 3, 4 collagens and FN1 are downregulated in 
senescent HSCs [16]. Thus, the timely shift of secretory profile to the inflammatory-
type SASP during senescence is critical for proper resolution of tissue damage and 
preventing excessive fibrosis.  20 
 
The dynamic nature of the SASP was also suggested in murine skin wound healing 
[22]. Accumulation of senescent stromal cells is an early event during healing, where 
PDGF-A, an early SASP factor, plays a critical role for proper wound healing. 
 15 
Interestingly, PDFGA is highly upregulated in NIS, but downregulated in RIS or DDIS 
HDFs [40].  
 
Whether NOTCH is involved in these tissue damage/repair models remains to be 
elucidated, but these studies underscore that timely regulation of the secretome 5 
composition during senescence plays an important role in restoration of tissue 
homeostasis after damage. Consistently, in the kidney, whilst acute activation of 
tubular epithelial Notch might be beneficial for tissue repair after ischemia-
reperfusion injury, chronic activation of Notch triggers senescence and renal fibrosis 
[55,81,82]. The timely downregulation of NOTCH activity and, hence, the TGF-β type 10 
SASP during senescence might contribute to inhibiting ‘over-healing’ of damaged 
tissues. Some patients undergo excessive fibrosis of skin wounds termed keloids, 
associated with exuberant fibrosis production; NOTCH signaling seems to be 
upregulated in this context [83].  
 15 
During embryonic development, senescence functions as a mechanism for 
developmental patterning, and these senescent cells demonstrate upregulation of 
TGF-β signaling and are subsequently eliminated by immune cells [19,20]. 
Considering the well-established role for NOTCH signaling in embryonic 
development, it would be interesting to investigate the involvement of NOTCH 20 
signaling and its spatial regulation in developmental senescence. 
 
Concluding Remarks 
It has become evident that senescence is far more than an autonomous tumor 
suppressor mechanism, but plays diverse and dynamic roles in tissue homeostasis 25 
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under both physiological and pathological conditions through its non-cell-
autonomous activities [35]. Similarly far from having a fixed composition, the SASP is 
a temporally-evolving entity involving a dynamic shift of its functionality during the 
transition to senescence. We are only just beginning to understand some of the non-
cell-autonomous activities of senescence apart from the secretome, with spatially 5 
restricted signaling. In certain contexts NOTCH signaling regulates a dynamic shift of 
SASP composition and a spatial propagation of senescence phenotype, adding new 
layers to the control of the non-cell-autonomous activities of senescence in space 
and time. Its potential significance in tissue damage/repair is discussed above.  
Senescent cells, through the inflammatory SASP, also play a key role for promoting 10 
cellular plasticity of adjacent cells in vivo [23-26]. Interestingly, it was shown that 
Notch inhibition can improve reprograming of mouse and human keratinocytes [84]. 
Whether or not the Notch-mediated secretory switch and/or lateral induction of Notch 
signaling contribute to cellular plasticity in keratinocytes and other contexts needs 
further study. While the significance of such temporospatial regulation of the SASP in 15 
tissue homeostasis is conceivable, its functional importance in OIS is not 
immediately clear. One speculative view would be that, at an early stage of OIS, 
NOTCH signaling amplifies the senescence-reinforcing TGF-β signaling through the 
lateral induction to ensure establishment of senescence, which then is followed by 
timely activation of inflammatory SASP and senescence surveillance.  20 
 
Senescence is a highly heterogeneous phenotype, in both autonomous and non-
autonomous contexts. Better understanding of the temporospatial regulation of the 
SASP in broader contexts will provide greater opportunities for development of 
senescence modulatory therapies. 25 
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Figure 1. Cellular senescence is an autonomous tumor suppressor mechanism 
providing diverse non-autonomous effects through the senescence associated 
secretory phenotype (SASP). 
Cellular senescence is a state of a stable cell cycle arrest mediated by the p53-p21 
and p16-Rb pathways. It can be induced by a wide-range of cellular stresses. In 5 
particular, senescence triggered by telomere dysfunction during repetitive cell 
division is termed replicative senescence, whereas other forms of stress-induced 
senescence can also develop (premature senescence). Senescent cells are highly 
secretory and have diverse impacts on the neighboring cells and the tissue 
microenvironment, co-ordinating the behavior of surrounding normal, senescent and 10 
transformed cells. Functionally it has been demonstrated to be critically important not 
only during tumorigenesis, but also wound healing and embryonic development. 
 
Figure 2. The canonical NOTCH signaling pathway. 
NOTCH signaling is transmitted from a ‘signal-sending’ cell to a ‘signal-receiving’ cell 15 
through ligand–receptor binding in a cell-cell contact dependent manner. In humans 
there are five DSL-family ligands, Jagged (JAG) 1 and 2, and Delta-like (DLL) 1, 3 
and 4, and four single-pass transmembrane-protein receptors, NOTCH 1, 2, 3 and 4. 
Upon ligand-receptor binding, the NOTCH receptor undergoes a series of proteolytic 
cleavage steps: metalloproteases of the ADAM/TACE family cleave the receptor 20 
ectodomain, allowing a second cleavage step by the γ-secretase complex releasing 
the NOTCH intracellular domain (NICD). The NICD can then translocate to the 
nucleus and bind to the DNA-binding protein RBP-J on chromatin, displacing co-
repressors from the complex and driving recruitment of transcriptional co-activators 
such as MAML1, p300 and others to form active transcription complexes on NOTCH-25 
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target genes, such as the HES and HEY family of transcription factors. 
Pharmacological or genetic disruption at each critical point in the pathway can inhibit 
NOTCH signaling. γ-secretase inhibitors (GSIs) or expression of the dominant-
negative form of MAML1 (DN-MAML) are examples. 
 5 
Figure 3. NOTCH signaling regulates a dynamic transition between two distinct 
SASPs through control of C/EBPβ during RAS-induced senescence. 
(A) At the early phase of RAS–induced senescence (RIS), upregulation of the active 
form of NOTCH1, the NOTCH1 intracellular domain (N1ICD) represses the 
expression and chromatin binding of the pro-inflammatory transcription factor 10 
C/EBPβ. This transient N1ICD upregulation is closely correlated with upregulation of 
TGF-β expression, thus resulting in an immunosuppressive and pro-fibrotic state 
resembling the secretory phenotype of N1ICD-induced senescence (NIS-type 
SASP). At the later phase downregulation of N1ICD permits de-repression of 
C/EBPβ. In cooperation with NF-κB this gives rise to a pro-inflammatory and 15 
fibrolytic secretome (RIS-type SASP) through expression of inflammatory cytokines 
such as IL6 and IL8. (B) IL1A is a direct target of C/EBPβ. The promoter and 
upstream enhancers of IL1A associate as a higher order chromatin structure where 
C/EBPβ binds and activates ILA transcription. N1ICD controls an IL1α - C/EBPβ-
mediated inflammatory loop during RIS by regulating C/EBPβ activity, confirming 20 
NOTCH1 signaling as a master regulator in switching-over between the NIS- and 
RIS-type SASP (see also A).  
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Box 1. Lateral inhibition and induction by juxtacrine signaling 
NOTCH-induced lateral inhibition or induction are modes of juxtacrine signaling 
described in embryonic development, where these processes determine cell fate and 
tissue domain specification by cell-cell contact dependent communication.  
Lateral inhibition of NOTCH signaling creates a divergence in NOTCH signal and 5 
therefore cell fate between sending and receiving cells through a negative feedback 
loop. (Figure I. A) A certain cell (light blue circle) among an otherwise homogenous 
population starts exhibiting higher NOTCH-ligand expression (L) than surrounding 
cells, which leads to upregulation of NOTCH activity (N) in the signal-receiving cells 
(light yellow circle). This elevated NOTCH activity represses ligand expression 10 
through transcriptional regulation of the effector gene (p), resulting in reduced 
reciprocal signaling from receiving to sending cell, further de-repressing ligand 
expression. This negative feedback loop amplifies the difference in the ligand 
expression and NOTCH activity of each cell and eventually the ‘ligand-high’ signal-
sending cell (blue circle) is surrounded by ‘NOTCH-high’ signal-receiving cells (red 15 
circle(s)). The most well known example of this behavior operates when embryonic 
proneural clusters divide into sensory organ precursors (SOP) (future neurons) and 
supporting cells at the late stage of inner ear development.  Cells differentiating into 
SOP express higher levels of ligand, repressing ligand expression in the surrounding 
cells and inhibiting further neuronal generation [76]. Forced expression of Notch-20 
ligand Dl1 in the chick retina leads all cells to become supporting cells due to mutual 
lateral inhibition, whereas interruption of this pathway causes all cells to become 
neurons, emphasizing the importance of this system in differentiating cell fate [85]. 
Although less well described, lateral induction of NOTCH signaling is observed in 
early progenitor domain specification and is mediated by a positive feedback loop. 25 
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(Figure I. B) The ‘NOTCH-high’ signal-receiving cell upregulates NOTCH-ligand 
expression (dark-red circle); as a consequence, this efficiently returns NOTCH 
signaling back to the neighboring cells (light-yellow circle). The positive feedback 
loop delivers trans-activation of NOTCH signaling, delivering co-ordinate cellular 
behavior across a tissue. This mode of signaling is found in the early stage of 5 
developing mouse otic epithelium. Ectopic expression of N1ICD (Notch1 intracellular 
domain) leads to the ectopic development of sensory-type epithelium throughout the 
inner ear due to a Jag1-dependent lateral spreading of Notch signaling [77].  
The molecular basis of the decision to induce or repress NOTCH-ligand is not 
known, but may involve the strength of the NOTCH signal transmitted by different 10 
members of the NOTCH ligands [86]. 
 
 
 1 
x NOTCH signaling is dynamically regulated during senescence 
 
x NOTCH1 signaling reciprocally regulates inflammatory cytokines and TGF-β 
during senescence 
 5 
x NOTCH1 signaling suppresses IL1α through downregulation of the 
transcription factor C/EBPβ  
 
x The NOTCH1-JAG1 pathway mediates cell-cell-contact dependent lateral 
induction of senescence 10 
 
 
  
Trends Box
 1 
x How is NOTCH activation and signaling regulated during senescence? 
 
x How general is the involvement of NOTCH in senescence? 
 
x What is a functional significance of temporospatial regulation of 5 
senescence in broader contexts? 
 
x What is the mechanism behind the NOTCH-mediated regulation of 
TGF-β and C/EBPβ during senescence? 
 10 
x Does dysregulation of NOTCH-mediated SASP switching contribute to 
aging and age related phenotypes? 
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